# ADDICTION SCIENCE & CLINICAL PRACTICE EDITORIAL BOARD

#### Linda Chang, M.D.

Professor, Department of Medicine John A. Burns School of Medicine University of Hawaii Honolulu, Hawaii

#### Hendrée Jones, Ph.D.

Associate Professor of Behavioral Biology Research Director, Center for Addiction and Pregnancy Program Director, Cornerstone Department of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, Maryland

#### Thomas R. Kosten, M.D.

Jay H. Waggoner Chair and Professor of Psychiatry and Neuroscience Baylor College of Medicine Houston, Texas

### Patricia Molina, Ph.D.

Ashman Professor, Department of Physiology Louisiana State University Health Sciences Center New Orleans, Louisiana

#### Edward V. Nunes, M.D.

Professor of Clinical Psychiatry Columbia University College of Physicians and Surgeons New York, New York

## James Sorensen, Ph.D.

Professor of Psychiatry University of California, San Francisco San Francisco General Hospital Medical Center San Francisco, California

#### Claire E. Sterk, Ph.D.

Senior Vice Provost for Academic Planning and Faculty Development Charles Howard Candler Professor of Public Health Emory University Atlanta, Georgia

Betty Tai, Ph.D. Director, Center for the Clinical Trials Network National Institute on Drug Abuse Bethesda, Maryland

#### Nancy Waite-O'Brien, Ph.D. Consultant The Betty Ford Center Rancho Mirage, California

# A Note From NIDA's Director

he rehabilitation of substance-abusing criminal offenders is an urgent issue for public health and public safety. In addition, improving treatment for these individuals could be a key to raising the overall success rates in the Nation's drug abuse treatment system. In some States, as many as two-thirds of those who enroll in community treatment programs do so under judicial mandate (see "Drug Abuse Treatment Beyond Prison Walls," page 24). Yet, recent meta-analyses suggest that substance-abusing offenders benefit less from interventions to reduce recidivism or drug abuse than do substance-abusing nonoffenders or offenders who are not involved with drugs: The findings showed smaller intervention effects in study populations consisting exclusively of substance-abusing offenders than in general substance abuse or offender populations (see "Interventions to Promote Successful Re-Entry Among Drug-Abusing Parolees," page 6).

To meet the challenge and gain the benefits of improving care for substance-abusing offenders, NIDA launched the Criminal Justice–Drug Abuse Treatment Studies (CJ-DATS) project (*www.cjdats.org*) in 2002. In the project's first 6 years, CJ-DATS researchers have conducted large-scale surveys of treatment availability and effectiveness, setting a baseline for measuring improvements; developed specialized screening and assessment batteries for drug-abusing offenders; and generated and tested strategies to help parolees re-engage with their communities. A second phase of the CJ-DATS project, now under way, addresses implementation issues, including policies and practices to integrate justice and treatment systems and practices.

In 2006, NIDA published *Principles of Drug Abuse Treatment for Criminal Justice Populations*, codifying the lessons learned from CJ-DATS and other research (*drugabuse.gov/PODAT\_CJ/principles*). The response to the booklet makes clear that the sense of urgency on this issue is widespread; it has become one of the most requested single publications in NIDA's history.

Nora D. Volkow, M.D.

Director National Institute on Drug Abuse